Background {#Sec1}
==========

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a major pathogen responsible for various hospital-acquired and community-associated infectious worldwide \[[@CR1]\]. Because of strong resistance to antibiotics, treatment of MRSA infections is challenging in clinical anti-infective therapy, leading to high risk of mortality and expensive medication \[[@CR1]\].

Skin and soft tissue infections (SSTIs) constitute the common diseases caused by *S. aureus*, including MRSA \[[@CR2]\], which can be treated with topical antibiotics mupirocin (MUP) and fusidic acid (FA) \[[@CR3]\]. However, unreasonable long-term use of these drugs leads to the emergence of resistance, which is a significant public health concern \[[@CR3]\]. Therefore, novel topical antimicrobial agent retapamulin (RET) is developed for the treatment of *S. aureus* SSTIs \[[@CR3]\].

MUP resistance in staphylococcus is divided into two phenotypes: high-level (MuH, minimum inhibitory concentration (MIC) ≥ 512 μg/mL) and low-level (MuL, MIC = 8--256 μg/mL) \[[@CR3], [@CR4]\]. The MuH is mediated by gene *mupA* or *mupB*, and the MuL is related to point mutations in the chromosomal isoleucyl-tRNA synthetase gene (*ileS*) \[[@CR3], [@CR5]\]. Previous studies showed that mutations in *fusA* or *fusE* in chromosome confer high-level FA resistance (FAH), and acquired *fusB*-*D* genes that mediate low-level resistance (FAL) \[[@CR3], [@CR6], [@CR7]\]. RET has been licensed in USA and Europe for the topical treatment of SSTIs caused by methicillin-sensitivity *S. aureus* and *Streptococcus pyogenes* \[[@CR8]\]. The RET resistance in *S. aureus* is often mediated by the point mutations of ribosomal protein L3 (encoded by *rplC*) or the 23S rRNA V domain, or efflux pumps VgaA/Av/A~LC~/B/C/E, LsaA-C/E and SalA, or methylation of the 23S rRNA subunit (methylated by methyltransferase encoded by chloramphenicol-florfenicol resistance (*cfr*) gene) \[[@CR3], [@CR9], [@CR10]\].

Several previous studies reported the resistance of MUP and FA in Eastern China \[[@CR11]--[@CR14]\]. However, since Eastern China is a region with a vast territory, the antibiotic resistance spectrum and the resistance mechanisms may be diversified in different hospitals. Therefore, the data on the resistance of both drugs in clinical isolates of *S. aureus* are limited. To the best of our knowledge, there is no information on RET resistance in China.

In this study, we determined the prevalence of MUP, FA and RET resistance among MRSA isolates from Shanghai and Zhejiang province in Eastern China, and analyzed the underlying resistance mechanisms. Furthermore, PFGE and MLST analysis were also carried out for the genetic characterization of resistant isolates.

Results {#Sec2}
=======

Prevalence of MUP, FA and RET resistance {#Sec3}
----------------------------------------

A total of 1206 MRSA isolates were screened using broth microdilution assay, and 49 MuH, 12 MuL, 6 FAH, 6 FAL, 2 RET-resistant and 1 MuH-RET-resistant isolates were identified. The detailed MIC data of the MUP, FA and RET resistance isolates were listed in Fig. [1](#Fig1){ref-type="fig"}. Although 75.1% isolates in this collection were obtained from respiratory samples, the resistance rates of these strains to MUP, FA and RET did not differ significantly as compared to those obtained from wound secretion, the second most common specimen type (Table [1](#Tab1){ref-type="table"}). Fig. 1Molecular characteristics, antibiotic MICs and sources of 76 clinical MRSA isolates with MUP, FA and/or RET resistance. The right panel shown the strain number, PFGE types (isolates with \> 80% similarity were classified into the same type), MLST results, antibiotics MICs (MUP, FA and RET) and strain sources (including sample type, ward and hospital)Table 1Resistance of MRSA isolates from respiratory samples and wound secretion to mupirocin, fusidic acid and retapamulinResistanceNo. (%) of resistant isolatesχ^2^*P*Respiratory samples (*n* = 906)Wound secretion (*n* = 200)Mupirocin51 (5.6%)7 (3.5%)1.4950.292Fusidic Acid8 (0.9%)4 (2.0%)2.1700.246^a^Retapamulin2 (0.2%)1 (0.5%)0.5400.451^aa^, Fisher's exact test

Mechanisms of MUP resistance {#Sec4}
----------------------------

A total of 49 MuH and 1 MuH-RET resistant isolates contained the *mupA* gene, and no isolates were *mupB* positive (Table [2](#Tab2){ref-type="table"}). The sequences of *Smr*, *Mrm* and *Lmr* DNA fragments were compared to the known *ileS* gene of *S. aureus* (Gene bank accession no. X74219). The findings showed that the 12 MuL isolates possessed N213D mutation in the Smr fragment, and 2 MuL isolates had V588F mutation in the Mrm fragment. No mutations were identified in the Lmr fragment. The mutations were accompanied by different MICs: N213D/V588F, 8 and 32 μg/mL (1 isolate each); N213D, 8 (1 isolate), 32 (2 isolates), 64 (1 isolate) and 128 μg/mL (6 isolates) (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). There was not significant difference in the distribution of MIC values between isolates with the single mutation N213D and the double mutation N213D/V588F (*P* = 0.077). In addition, no *mupA* or *mupB* gene was detected in MuL isolates. Table 2Resistance mechanisms of 76 mupirocin, fusidic acid and/or retapamulin-resistant clinical MRSA isolatesMupirocinFusidic acidRetapamulinStrainPhenotype*mupAmupB*IleS mutationPhenotypeMutation*fusBfusCfusD*PhenotypeMutation*cfrvagA*/*Av*/*A*~*LC*~/*B*/*C*/*ElsaA*-*ClsaEsalA*SmrMrmLmrFus AFus E*rplC*23S rRNA VPT300MuL----N213DV588F--SS546MuL----N213D----SS532MuL----N213D----SS472MuL----N213D----SS526MuL----N213D----SS606MuL----N213D----SS673MuL----N213D----SS777MuL----N213D----SS635MuL----N213D----SS575MuL----N213D----SSWU9MuL----N213DV588F--SS308MuL----N213D----SS110SFAHL461K----+--S829SFAHH457Q----+--SPT301SFAHL461K----+--SPT308SFAHL461K----+--SLY26SFAHE8K, V90I, L461K--------SLY32SFAHH457Y--------S696SFAL----+----S755SFAL----+----S783SFAL----+----S361SFAL----+----S611SGSFAL----+----S765SFAL----++--SLS964SSR----------+--58SSR--------------486MuH+--SR--------------PT343MuH+--SS355MuH+--SS370MuH+--SS519MuH+--SS409MuH+--SS671MuH+--SS443MuH+--SS530MuH+--SS120MuH+--SS322MuH+--SS328MuH+--SS448MuH+--SS474MuH+--SS565MuH+--SS600MuH+--SS623MuH+--SS642MuH+--SS694MuH+--SS697MuH+--SS70MuH+--SS701MuH+--SS717MuH+--SSPT317MuH+SS318MuH+--SS106MuH+--SS331MuH+--SS364MuH+--SS553MuH+--SS504MuH+--SS394MuH+--SS805MuH+--SS453MuH+--SS727MuH+--SS764MuH+--SS433MuH+--SS541MuH+--SS631MuH+--SS320MuH+--SS348MuH+--SS349MuH+--SS399MuH+--SS422MuH+--SS419MuH+--SS390MuH+--SS125MuH+--SS323MuH+--SS386MuH+--SS513MuH+--SS314MuH+--SS*MRSA*, methicillin-resistant *S. aureus*; +, positive; ---, negative or no mutation; IleS, isoleucyl-tRNA synthetase; MuH, high-level mupirocin resistance; MuL, low-level mupirocin resistance; FAH, high-level fusidic acid resistance; FAL, low-level fusidic acid resistance; *vagA*/*Av*/*A*~*LC*~/*B*/*C*/*E*, including *vagA*, *vagAv*, *vagA*~*LC*~, *vagB*, *vagC* and *vagE*; *lsaA*-*C*, including *lsaA*, *lsa*B and *lsaC* R, resistance; S, susceptibility

Mechanisms of FA resistance {#Sec5}
---------------------------

To uncover the mechanisms of FA resistance among 6 FAH isolates, the full-length of *fusA* and *fusE* genes were sequenced and compared to those of *S. aureus* ATCC 25923. Herein, we identified 2 isolates that contained H457 missense mutation (H457Q and H457Y, accompanied by MICs of 128 and 16 μg/mL, respectively), while 3 harbored the L461K mutation (MIC = 128 μg/mL), and 1 (MIC = 64 μg/mL) simultaneously possessed L461K, E8K and V90I mutations in FusA (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). All the FA resistance isolates were evaluated for *fusB*, *fusC* and *fusD*. Among the 6 FAH isolates, 4 carried the *fusC* gene. Furthermore, all the 6 FAL isolates were *fusB*-positive, and only one carried *fusC* gene (Table [2](#Tab2){ref-type="table"}). No mutations were found in *fusE*, and no isolates were *fusD* positive.

Mechanism of RET resistance {#Sec6}
---------------------------

1/3 isolates with resistance to RET harbored the *lsaE* gene, and the remaining two displayed negative findings for all the resistance mechanisms tested (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}).

PFGE {#Sec7}
----

The 76 isolates with MUP, FA and/or RET resistance were divided into 16 patterns: type A-P (Fig. [1](#Fig1){ref-type="fig"}). Among 49 MuH alone strains, 40 belonged to type B, 4 were type E, and each of the remaining 5 belonged to types A, F, J, K and N, respectively. One MuH-RET resistant isolate was also type B. Among 12 MuL isolates, 9 were type B, and 3 belonged to type A, M and N, respectively. Type C was the most frequent type in FAH strains (3/6; 50%). Type G was the most common pattern in FAL strains (4/6; 66.7%). Two MRSA resistant to RET alone belonged to types O and H, respectively.

MLST {#Sec8}
----

Fifteen STs were identified among the 76 isolates studied (Fig. [1](#Fig1){ref-type="fig"}). ST764 (24/76, 31.6%) was the most frequent pattern, followed by ST630 (11/76, 14.5%), ST239 (9/76, 11.8%) and ST5 (7/76, 9.2%) and 11 additional STs, namely ST4631 and ST1821 (4/76 each, 5.3%), ST9, ST3262 and ST4184 (3/76 each, 3.9%), ST1 and ST20 (2/76 each, 2.6%), ST965, ST398, ST4359 and ST97 (1/76 each, 1.3%).

Discussion {#Sec9}
==========

MUP is effective for the prevention and treatment of MRSA SSTIs. However, the resistance (including MuL) is beneficial for MRSA treatment and eradication failure \[[@CR15], [@CR16]\]. The prevalence rate of MUP resistance in MRSA clinical isolates varies from 0.5--10.1% for MuH and 2.4--8.6% for MuL in USA, 0--75% for MuH and 0--46.7% for MuL in Asia, and from 0.8--98% for MuH and 0--31.2% for MuL in Europe \[[@CR15]\]. In the present study, the isolation rates of MuH and MuL were low: 4.1% (50/1206) and 1.0% (12/1206), respectively. Recent studies displayed that the prevalence of MuH is mediated by plasmid-borne *mupA* gene \[[@CR15]\], which is the same as our results. Although *mupB*, also a plasmid-borne gene, is correlated with MuH \[[@CR5]\], the mechanism is rarely examined in staphylococci, including the isolates investigated in this study. The point mutations in the *ileS* gene, resulting in amino changes in MUP-binding site (located in amino acids 450--650, also named Rossman fold), are the main mechanisms determining MuL \[[@CR15], [@CR17]\]. V588F and V631F are well identified frequent mutations in IleS responsible for MuL \[[@CR15]\]. In this study, only two MuL isolates (PT300 and wu9) contained the V588F mutation, and no MuL isolates harbored the V631F mutation. Notably, all MuL isolates harbored the N213D mutation that was located in a hotspot amino acid sequence between 200 and 350, as described by Lee et al. \[[@CR17]\]. The N213D mutation has been previously reported and are considered to have no impact on the sensitivity of MUP \[[@CR18]\]. Although the *mupA* gene located on the chromosome is also associated with MuL \[[@CR3]\], we did not detect the gene in our MuL isolates. Also, no other mutations in IleS were found. Lee et al. \[[@CR17]\] reported that a mutation of S634F that confers phenotype of susceptibility or MuL in diverse isolates. In view of the above reasons, the contribution of N213D mutation to MuL should be evaluated further.

FA is a steroidal antimicrobial agent that suppresses the production of bacterial proteins by stopping the dissociation of elongation factor G (EF-G) from ribosome \[[@CR6], [@CR19]\]. Clinically, the main application of topical FA is for the treatment of SSTIs and decolonization of *S. aureus*, including MRSA; this method is similar to that of MUP \[[@CR3]\]. The prevalence of FA resistance reported by recent large studies varies in MRSA isolates from USA (0--0.3%), Australian (4.1--5.1%), Denmark (17.8%), Greece (57.0%) and other European countries (9.9%) \[[@CR3]\]. In China, the resistance levels in MRSA are also different in different areas, for example, 3.0--5.3% in MRSA from Beijing, Shanghai, Shenyang and Shenzhen cities \[[@CR12], [@CR20]\], and 27.1% in MRSA from Wenzhou city \[[@CR11]\]. Compared to the aforementioned data from China, our results showed a very low resistance rate (12/1206, 1.0%).

In *S. aureus*, the mutations in *fusA* (encoding EF-G) or *fusE* (coding for ribosome protein L6, RplF) lead to a decreased affinity of FA for the EF-G ribosome complex \[[@CR3], [@CR21]\]. About \> 30 point mutations in FusA sequence were described; however, only a few were experimentally verified to play a role in FA resistance \[[@CR3], [@CR22], [@CR23]\]. The V90I mutation in domain I (amino acids 1--280) and H457Y, H457Q and L461K mutations in domain III (amino acids 404--480) were observed in this study, and have been previously identified causing FAH in *S. aureus* \[[@CR21], [@CR22], [@CR24]\]; also, L461K is the most prevalent mechanism among clinical FAH *S. aureus* strains \[[@CR3]\]. L461K also existed in the majority (4/6, 80%) FAH isolates, leading to FA MICs ≥64 μg/mL in the current study. One novel substitution with E8K in domain I was identified in addition to V90I and L461K mutations in the FAH isolate. However, whether the novel mutation is associated with FA resistance is not yet clarified.

Protection of EF-G by FusB family molecules is another mechanism conferring the resistance (low-level) of FA \[[@CR3]\]. FusB family proteins (including FusB, FusC, and FusD) can restore the translation of protein by binding to EF-G in the presence of FA \[[@CR3]\]. Previous studies showed that *fusB* was the most prevalent in Netherlands and mainland China \[[@CR11], [@CR12], [@CR25]\], and *fusC* primarily existed in isolates from Taiwan, Australia, USA and European \[[@CR26]--[@CR28]\]. In our isolates with FA resistance, *fusB* existed in all FAL isolates (6/6), and *fusC* was most prevalent in FAH isolates (4/6, 66.7%). The *fusD* gene was identified in *Staphylococcus saprophyticus*. The gene is related to the "intrinsic resistance of FA" among this species \[[@CR19]\]. Hitherto, this determinant is rarely detected in *S. aureus* strains.

RET is a semisynthetic pleuromutilin drug that represses the synthesis of bacterial proteins by interacting with domain V of 50S ribosomal subunit \[[@CR3]\]. This drug has a potency to act as an alternative to MUP to eradicate the *S. aureus* colonization, except when used for the treatment of *S. aureus*-induced SSTIs \[[@CR8], [@CR29]\]. Currently, limited data are available among clinical *S. aureus* strains worldwide. The resistance rates of 664 UK *S. aureus* (74% are MRSA), 155 USA MRSA, 403 USA MRSA, and 400 USA *S. aureus* from several studies were 0.15, 2.6, 0.25, and 9.5%, respectively \[[@CR8], [@CR29]--[@CR31]\]. In this study, the prevalence of RET resistance was very low (3/1206, 0.24%). In the UK and USA, the RET resistance among *S. aureus* or MRSA with MUP resistance was \< 1--2.6% \[[@CR8], [@CR31]\]. In the present study, only one MRSA isolate was observed to have resistance to both RET and MUP. For RET resistance in staphylococci, except mutation and/or methylation of ribosomal protein and rRNA, the ABC-F proteins (efflux pumps) encoded by three types of genes (*vga*, *lsa* and *sal*) were alsocritical mechanisms \[[@CR32]\]. However, in our 3 RET-resistant isolates, only one was confirmed to contain the *salE* gene. The *salE* gene confers the resistance to pleuromutilins, lincosamides and streptogramin A \[[@CR32]\]. Fortunately, the gene was localized on the chromosome or non-conjugative plasmid (pV7073) \[[@CR32]\], which limits its transmission among staphylococci. For two strains we could not clarify phenotypic resistance to the detected resistance determinants, implying that there possibly exists other gene or gene variant leading to RET resistance.

ST239 and ST5 are two predominant sequence types in China. However, the strains identified in this study mainly belonged to ST764 (31.6%), which was more than the total percentage of ST239 and ST5 (16/76, 21.1%). Early investigation showed that most of FA-resistant MRSA belong to ST239 and ST5 \[[@CR7], [@CR27]\]. However, our findings showed no FA-resistant strains were these two types. ST764 MRSA, first reported in Japan, is a single-locus of ST5 nosocomial MRSA clone with or without the arginine catabolic mobile element (ACME, a feature of CA-MRSA) \[[@CR33], [@CR34]\]. In recent years, several studies reported the *S. aureus* clone with ST764 in China \[[@CR13], [@CR35]\]. In this study, ST630 (14.5%) was the second most common type, which also became a prevalent *S. aureus* clone causing SSTIs in Wenzhou region, Zhejiang province, China \[[@CR36]\]. Figure [1](#Fig1){ref-type="fig"} shows that 66.7% (4/6) FAL isolates belonged to ST630 (PFGE G-ST630), which was similar to the previous report \[[@CR9]\]. Notably, 50% (6/12) MUL isolates and 39.0% (16/41) MUH isolates with MIC ≥1024 μg/mL were PFGE B-ST764, and were identified from the same hospital (Shanghai General Hospital) (Fig. [1](#Fig1){ref-type="fig"}), indicating clone transmission. In addition, the spread of other MRSA clones with different genetic patterns, such as PFGE B-ST1821, PFGE B-ST239 (4 isolates each), PFGE B-ST5 and PFGE B-ST630 (3 isolates each) were also responsible for the increased MUH in this hospital. It should be noted that some resistant isolates had the same PFGE pattern (such as PFGE B, C, E, G or M), although the ST types were diverse from each other (Fig. [1](#Fig1){ref-type="fig"}). These finding hint that these isolates might be clonally related.

Conclusions {#Sec10}
===========

In this study, the MRSA isolates exhibited a low prevalence of resistance to MUP, FA and RET, especially to the latter two, and cross-resistance to the three antibiotics was rare. The *mupA* gene mechanism mediated MuH. The contribution of the N213D mutation in IleS found in our MuL isolates that decreased the resistance of MUP is yet unclear. FusA mutations, FusB and FusC were the frequent genetic mechanisms that mediate FA resistance. Phylogenetic detection showed the transmission of multiple clones, especially PFGE B-ST764 clone that made a major contribution to the increased MUP resistance in this collection of isolates. Owing to the concern of resistance development and clonal dissemination in healthcare, continuous surveillance for the resistance of these topic antibiotics in *S. aureus* is essential in China.

Methods {#Sec11}
=======

Bacterial isolates {#Sec12}
------------------

A total of 1206 non-duplicate MRSA isolates from various clinical specimens were collected from 8 hospitals in Shanghai and Zhejiang province, Eastern China (Shanghai General Hospital (1037 isolates from July 2010 to June 2015), Ruijin Hospital (22 isolates during January 2011 to December 2011), Shanghai Sixth People′s Hospital (36 isolates between Decermber 2010 and Decermber 2012), Shanghai People′s Hospital of Putuo District (45 isolates from January 2013 to May 2014), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (21 isolates from February 2014 to September 2014), Shanghai Armed Police Corps Hospital (9 isolates from January 2014 to June 2014), Zhejiang Xiaoshan Hospital (8 isolates from March 2012 to October 2012) and The Central Hospital of Lishui City, Zhejiang Province (28 isolates, July 2013 to September 2014)). The majority of these isolates were obtained from respiratory samples (906/1206, 75.1%) and wound secretion (200/1206, 16.6%). The MRSA isolates were frequently detected in intensive care units, respiratory medicine, geriatric medicine, thoracic surgery and nephrology wards causing maximal impact. All isolates were identified using VITEK microbial identification system (bioMérieux, Marcy l′ Etoile, France). The resistance to methicillin was detected with a 30 μg cefoxitin disk (Oxoid, Basingstoke, UK) \[[@CR4]\]. MuH (MIC ≥512 μg/mL), MuL (MIC = 8--256 μg/mL), FAH (MIC ≥8 μg/mL), FAL (MIC = 2--4 μg/mL) and RET resistance (MIC ≥1 μg/mL was defined as resistance in this study) were screened from all the isolates collected by broth microdilution method \[[@CR4], [@CR6], [@CR14], [@CR37]\]. For three-antibiotic (MUP, FA and RET) resistant isolates, the methicillin resistance was further confirmed by the amplification of *mecA* and *mecC* genes \[[@CR35]\]. MUP, FA and RET were purchased from Shanghai Boyle Chemical Co., Ltd., China. Cation-adjusted Mueller-Hinton broth was produced by Shanghai Comagal Microbial Technology Co., Ltd., China. *S. aureus* ATCC 25923 and ATCC 29213 were used as quality control strains for antibiotic susceptibility testing.

Total DNA extraction {#Sec13}
--------------------

The cultures of MRSA with MUP, FA and/or RET resistance were incubated with lysostaphin (1 mg/mL) (Sangon Biotech, Shanghai, China) at 37 °C for 0.5 h. Then, the DNA was extracted according to the instructions of the bacterial genomic DNA kit (Tiangen Biotech, Beijing, China), and utilized as a template for PCR assays.

Detection of MUP, FA, and RET resistance genes {#Sec14}
----------------------------------------------

PCR was used to detect the factors mediating MUP (*mupA*, *mupB* and *ileS* (amplifying three fragments of *Smr*, *Mrm* and *Lmr*, which might possess the mutations mediating mupirocin resistance)), FA (*fusA*, *fusB, fusC*, *fusD* and *fusE*) and RET (*rplC*, *cfr*, *vgaA*/*Av*/*A*~*LC*~/*B*/*C*/*E*, *lsaA*-*C*/*E*, *salA* and 23S RNA V) resistance \[[@CR5], [@CR7]--[@CR10], [@CR26], [@CR29], [@CR38]--[@CR41]\]. The primers and programs for the amplification of genes are presented in Table [3](#Tab3){ref-type="table"}. The DNA sequencing of one randomly selected PCR product for *mupA*, *mupB*, *fusB*-*D*, *cfr*, *vgaA*/*Av*/*A*~*LC*~/*B*/*C*/*E*, *lsaA*-*C*/*E*, and *salA* was used for the identification of target fragments. All the PCR products for *ileS*-*Smr*, *ileS*-*Mrm*, *ileS*-*Lmr*, *fusA*, *fusE*, *rplC* and 23S RNA V were sequenced to determine the putative mutations. Table 3Primers and PCR conditions for detecting mupirocin, fusidic acid and retapamulin resistance genes in this studyGenePrimer namePrimer sequence (5′-3′)PCR amplification programSizeReferenceMolecular mechanisms related to mupirocin resistance*mupAmupA*-FTATATTATGCGATGGAAGGTTGGInitial pre-denaturation at 94 °C for 5 min; 30 cycles of denaturation (30 s at 94 °C), annealing (30 s; at 53 °C for *mupA*, and 55 °C for *mupB*, *Smr*, *Mrm* and *Lmr*), and extension (50 s at 72 °C), followed by a final extension step of 7 min at 72 °C457 bp5*mupA*-RAATAAAATCAGCTGGAAAGTGTTG*mupBmupB*-FCTAGAAGTCGATTTTGGAGTAG674 bp*mupB*-RAGTGTCTAAAATGATAAGACGATC*ileS* (including the following 3 fragments)*SmrSmr*-FATAAAGGTAAAAAGCCAGTTTATTGGT200 bp38*Smr*-RTAATCGCAACATTTGATGGAATTGTC*MrmMrm*-FTCCCAGCAGATATGTATTTAGAAGGT450 bp*Mrm*-RAACCACTTGGTCAGGTACAATCACA*LmrLmr*-FGTAAATCTTTAGGTAATGTGATTGTAC690 bp*Lmr*-RTCTTCTTTAACATGTGGTGTATGAGAMolecular mechanisms associated with fusidic acid resistance*fusAfusA*-FTTTACCCTGAGTGTGTTCTInitial pre-denaturation at 94 °C for 5 min; 30 cycles of denaturation (30 s at 94 °C), annealing (30 s; at 53 °C for *fusB*-*D* and *fusE*, and 40 °C for *fusA*), and extension (2 min, at 72 °C for *fusA*; 50 s, at 72 °C for other genes), followed by a final extension step of 7 min at 72 °C2250 bp7*fusA*-RTACATTTAAGCTCACCTTGT*fusBfusB*-FTCATATAGATGACGATATTG496 bp26*fusB*-RACAATGAATGCTATCTCGAC*fusCfusC*-FGATATTGATATCTCGGACTT128 bp*fusC*-RAGTTGACTTGATGAAGGTAT*fusDfusD*-FTGCTTATAATTCGGTCAACG525 bp*fusD*-RTGGTTACATAATGTGCTATC*fusEfusE*-FCCTAGTGACGTAACAGTAAC505 bp*fusE*-RCGGCGWACRTATTCACCTTGMolecular mechanisms associated with retapamulin resistance*rplCrplC*-FAACCTGATTTAGTTCCGTCTAInitial pre-denaturation at 94 °C for 5 min; 30 cycles of denaturation (30 s at 94 °C), annealing (30 s; at 50 °C for *vgaA* and *vgaA*~*LC*~, 52 °C for *vgaB*, *vagC*, *vgaE*, *lsaA*-*C* and *lsaE*, and 55 °C for *rplC*, *cfr*, *vgaAv*, *salA* and 23S RNA V), and extension (2 min, at 72 °C for *vgaC*, *vgaE* and *salA*; 50 s, at 72 °C for other genes), followed by a final extension step of 7 min at 72 °C822 bp8*rplC*-RGTTGACGCTTTAATGGGCTTA*cfrcfr*-FGAGATAACAGATCAAGTTTTA1050 bp39*cfr*-RCGAGTATATTCATTACCTCAT*vgaAvgaA*-FTCACATGATCGCGCTTTTTTAGAT770 bp29*vgaA*-RTCGCTCTCCACCACTTAAGACACT*vgaAvvgaAv*-FCTCTTTGTACGAGTATATGG770 bp40*vgaAv*-RGTTTCTTAGTAGCTCGTTGAGC*vgaA*~*LC*~*vgaA*~*LC*~-FCATTATCGCCATCTGTCA541 bp9*vgaA*~*LC*~-RAATTCTTCCGAAGGTTCA*vgaBvgaB*-FTGACAATATGAGTGGTGGTG577 bp*vgaB*-RGCGACCATGAAATTGCTCTC*vgaCvgaC*-FCGTATGCCCAGAGTGAG1073 bp*vgaC*-RGAGTGCTTCCGTATCCA*vgaEvgaE*-FGAAATATGGGAAATAGAAGATGG995 bp*vgaE*-RTGATTCTCTAACCACTCTTC*lsaAlsaA*-FACCGTGAAGGTGATAAGT500 bp*lsaA*-RTTGGGTGTAATCTAACTGAT*lsaBlsaB*-FTCCACTGCCGTTCTTTCC715 bp*lsaB*-RAGCCATGTACCGTCCTTT*lsaClsaC*-FGGCTATGTAAAACCTGTATTTG429 bp*lsaC*-RACTGACAATTTTTCTTCCGT*lsaElsaE*-FTTGTACGGAATGTATGG675 bp*lsaE*-RTTCGCTTCTATTAAGCACTCTT*salAsalA*-FCGATGAACCAACAAACCACA981 bp10*salA*-RAGGACCGAACCTTGAAATGA 23S RNA V23S RNA-FTGGGCACTGTCTCAACGA634 bp4123S RNA-RGGATAGGGACCGAACTGTCTCMLST typing43*arcCarcC*-FTTGATTCACCAGCGCGTATTGTCInitial pre-denaturation at 94 °C for 5 min; 30 cycles of denaturation (30 s at 94 °C), annealing (30 s; at 55 °C for 7 house-keeping genes), and extension (50 s, at 72 °C for other genes), followed by a final extension step of 7 min at 72 °C456 bp*arcC*-RAGGTATCTGCTTCAATCAGCG*aroEaroE*-FATCGGAAATCCTATTTCACATTC456 bp*aroE*-RGGTGTTGTATTAATAACGATATC*glpFglpF*-FCTAGGAACTGCAATCTTAATCC465 bp*glpF*-RTGGTAAAATCGCATGTCCAATTC*gmkgmk*-FATCGTTTTATCGGGACCATC429 bp*gmk*-RTCATTAACTACAACGTAATCGTA*ptapta*-FGTTAAAATCGTATTACCTGAAGG474 bp*pta*-RGACCCTTTTGTTGAAAAGCTTAA*tpitpi*-FTCGTTCATTCTGAACGTCGTGAA402 bp*tpi*-RTTTGCACCTTCTAACAATTGTAC*yqiLyqiL*-FCAGCATACAGGACACCTATTGGC516 bp*yqiL*-RCGTTGAGGAATCGATACTGGAAC

Pulsed field gel electrophoresis (PFGE) {#Sec15}
---------------------------------------

PFGE was performed for MUP, FA and/or RET resistant strains, as described previously \[[@CR42]\]. BioNumerics software 7.0 was used for the analysis of DNA fingerprint profiles. An 80% cutoff value was set to assess the similarity.

Multilocus sequence typing (MLST) {#Sec16}
---------------------------------

MLST was conducted by sequencing of the internal fragments of the 7 housekeeping genes, *arcC*, *aroE*, *glpF*, *gmk*, *pta*, *tpi* and *yqiL* on MUP, FA and/or RET-resistant MRSA using the primers (Table [3](#Tab3){ref-type="table"}), as described previously \[[@CR43]\]. Sequence types (STs) were determined based on the data from the MLST database for *S. aureus* (<http://saureus.mlst.net/>).

Statistical analysis {#Sec17}
--------------------

The difference of MUP, FA and RET-resistant rates of isolates from major samples was analyzed by Pearson's Chi-square test or Fisher's exact test using SAS 8.0 (SAS Institute, Cary, NC, USA). Student's t test was used to determine the difference in the distribution of MIC values between isolates with different mutations. A *P* value \< 0.05 (two-tailed) indicated significance.

FA

:   Fusidic acid

FAH

:   High-level fusidic acid resistance

FAL

:   Low-level fusidic acid resistance

IleS

:   Isoleucyl-tRNA synthetase

LSH

:   The Central Hospital of Lishui City, Zhejiang Province

MIC

:   Minimum inhibitory concentration

MLST

:   Multilocus sequence typing

MRSA

:   Methicillin-resistant *Staphylococcus aureus*

MuH

:   High-level mupirocin resistance

MuL

:   Low-level mupirocin resistance

MUP

:   Mupirocin

PCR

:   Polymerase chain reaction

PFGE

:   Pulsed-field gel electrophoresis

PT

:   Shanghai People's Hospital of Putuo District

RET

:   Retapamulin

SAH

:   Shanghai Armed Police Corps Hospital

SGH

:   Shanghai General Hospital

SSH

:   Shanghai Sixth People's Hospital

SGHA

:   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
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